23 Apr Zero dose PCV Children – dangerously exposed to pneumonia
This campaign is in support of World Immunisation Week, 24-30 April 2020. For more information visit https://wiw2020.org/
Children living in countries that do not offer the pneumococcal conjugate vaccine (PCV) are dangerously exposed to pneumonia, the biggest infectious killer in the world.
Prior to the COVID-19 pandemic, pneumonia killed an estimated 2.6 million people each year – more than any other infectious disease. Post COVID-19 this number will rise exponentially.
In this context, it is vital that all countries are protecting their populations, and especially their most vulnerable populations, with every tool available to prevent pneumonia from any causes.
The pneumococcal vaccine is one of the most powerful tools we have to prevent pneumonia, because it targets the leading bacterial cause – streptococcus pneumoniae. It is a highly effective vaccine. For example, after Kenya introduced the vaccine in 2011, the average annual incidence of severe pneumococcal disease dropped by 92% among children under five and hospital admissions fell sharply.
Accordingly, the World Health Organization (WHO) recommends that all children under five receive the pneumococcal vaccine and some national governments also recommend that the elderly receive it, as pneumonia is also a major cause of death among adults aged over 70 in most countries.
But not every country has followed these recommendations, and there are currently hundreds of millions of vulnerable children and adults who do not receive the pneumococcal vaccine.
They are dangerously exposed to pneumonia and at risk of spreading infection to others.
All vulnerable populations deserve to be protected with the pneumococcal vaccine, but this is even more critical during a pandemic of viral pneumonia. This is because high coverage of the pneumococcal vaccine not only reduces the risk of bacterial pneumonia among children and the elderly, but protects vulnerable populations from co-infections that can increase the risk of death from COVID-19. Both effects reduce demands on already stretched health systems.
This is why every country in the world needs to protect children and the elderly with the pneumococcal vaccine.
While Gavi, the Vaccine Alliance has a strong track record of supporting low income countries to introduce the pneumococcal vaccine among children, middle and high-income countries should immediately take the initiative and introduce the vaccine to fully protect their children and elderly populations.
How many zero dose PCV children are there in the world?
There are approximately 430 million children under the age of 15 living in countries with zero coverage of the PCV vaccine. This means that more than one out of every five children under 15 is not protected from the leading cause of bacterial pneumonia.
Where do zero dose PCV children live?
There are 54 zero dose PCV countries spread across every region of the world. The Western Pacific region is home to 290 million (67%) of zero dose PCV children, followed by the Eastern Mediterranean with 67 million (16%), and Africa with 27 million (6%). In contrast, Europe is home to 20 million (5%), Southeast Asia to 17 million (4%), and the Americas to 11 million (2%) zero dose PCV children.
What price are Zero dose PCV COUNTRIES paying?
The cost of this exposure is ultimately measured in children’s lives lost due to pneumonia – an estimated 90,000 every year in the zero dose PCV countries, or 10% of all pneumonia deaths among children under 15.
The zero dose PCV countries with the heaviest burdens of child pneumonia deaths include China, Chad, Egypt, South Sudan, Somalia, Guinea, Tajikistan, Viet Nam, Iraq and North Korea. Together these ten countries account for 94% of the 90,000 child pneumonia deaths occurring in zero dose PCV countries.
As most of the 54 zero dose PCV countries are also experiencing heavy burdens of pneumonia deaths among their elderly populations, protecting children with the PCV should have a significant impact on reducing infections and deaths from pneumonia among the elderly.
Although there are no routine estimates of pneumonia deaths prevented among the elderly with PCV vaccination among children, studies suggest that childhood PCV vaccination leads to substantial protection across the whole population within a decade.
What about COVID-19?
Although there is no evidence that PCV vaccination offers protection against COVID-19 infection, ensuring that all children are protected with PCV and the other pneumonia-fighting vaccines (Hib, pertussis and measles), will reduce the likelihood of co-infections with bacterial pneumonia and COVID-19 among both children and adults.
What must be done?
Introduction of the PCV should form part of national Pneumonia Control Strategies that address other preventive measures (child nutrition, air pollution, WASH) as well as diagnosis and treatment with pulse oximetry, oxygen therapies and the WHO-recommended child-friendly antibiotics.
The remaining 47 non-Gavi eligible countries should also announce the introduction of the PCV and a commitment to achieving 95% coverage within five years. Wide coverage of the PCV by 2025 will help countries reduce child pneumonia deaths and accelerate achievement of the Sustainable Development Goal (SDG) for child survival, which requires that every country reduce child deaths to at least 25 for every 1,000 babies born by 2030.
Fully protecting children with the PCV will also mitigate the effects of COVID-19 on all vulnerable populations by reducing the risk of bacterial pneumonia and co-morbidities that can significantly increase the risk of death.
COVID-19 has shown the world that all countries need national strategies to prevent and control pneumonia, especially among their most vulnerable populations.
Author: Leith Greenslade, Coordinator, Every Breath Counts Coalition
Photo credit: Save the Children
* Cook Islands, Nauru, North Korea, Samoa, Tonga, Turkmenistan, Tuvelu and Vanuatu.
Note: This analysis only looks at countries that have not yet introduced the PCV. It does not address the urgent need to increase coverage of the vaccine from the current global average of 47% to above 95% in the countries that have already introduced the vaccine.